Alfred E. Tiefenbacher GmbH & Co. KG is a privately held, family-owned international healthcare company founded in 1963. Headquartered in Hamburg, Germany, the company operates as the Tiefenbacher Group and employs over 800 people. It provides solutions across the entire pharmaceutical value chain, from development to market entry, in more than 80 countries.
As an operating company, Tiefenbacher's business encompasses several areas. A core competency is the distribution of active pharmaceutical ingredients (APIs). The company also develops, manufactures, and registers its own finished dosage forms (FDFs), including generic, value-added, and innovative medicines. Its product portfolio includes tablets, capsules, and highly potent drugs. Additionally, the group offers contract development and manufacturing (CDMO) services and is involved in medical devices and e-health solutions.
The company's patent litigation posture is that of an operating company defending its business. The provided data shows one tracked case where it is named as a defendant, consistent with a pharmaceutical manufacturer involved in generic drug patent challenges. This suit, filed in the Delaware District Court, does not indicate a pattern of patent assertion by Tiefenbacher.
The notable tracked case is Harmony Biosciences Management Inc et al. v. AET Pharma US Inc et al., filed in April 2026. This patent infringement lawsuit relates to Tiefenbacher's US subsidiary, AET Pharma US Inc., seeking approval to market a generic version of Harmony's narcolepsy drug, WAKIX® (pitolisant). AET is the remaining defendant in a broader litigation campaign by Harmony against multiple generic drug filers.